Article

Potential for false-positive staining with a rabbit monoclonal antibody to progesterone receptor (SP2) - Findings of the UK National External Quality Assessment Scheme for Immunocytochemistry and FISH highlight the need for correct validation of antibodies on introduction to the laboratory

Department of Pathology, University College London, London, England.
American Journal of Clinical Pathology (Impact Factor: 3.01). 04/2008; 129(3):398-409. DOI: 10.1309/2YXRLEQVPPNRWHGA
Source: PubMed

ABSTRACT This study focused on recent assessment results from the United Kingdom National External Quality Assessment Scheme for Immunocytochemistry and Fluorescence In-Situ Hybridisation breast hormone receptor module in which participants were asked to demonstrate progesterone receptors (PRs). The slides consisted of 3 infiltrating ductal breast carcinomas, previously classified as a high PR expresser, a moderate to low PR expresser, and a negative tumor. During this assessment, 2 commercial rabbit monoclonal antibodies, SP2 (Lab Vision/NeoMarkers, Fremont, CA), and 1E2 (Ventana, Tucson, AZ) were used by 15% of the participants. The SP2 rabbit monoclonal antibody showed false-positive and nonspecific staining on the previously established PR-tumor. This article highlights the necessity for all clinical laboratories to validate immunohistochemical methods and protocols when using newly marketed antibodies such as SP2; use composite tissue blocks with known levels of tumor expression such as a high, mid, and negative expression; and participate in internal and external quality assessment schemes, which can highlight potential technical issues in laboratory methods.

0 Followers
 · 
87 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: In land mobile systems, a distance of separation is needed to provide sufficient isolation between two systems so that they can operate without interference. In order to increase spectrum utilization, it is worth while to explore if such two systems can be brought closer together at an acceptable probability of interference. This paper introduces a methodology to calculate such a probability of interference, in a land mobile duplex system context
    Electrical and Computer Engineering, 1996. Canadian Conference on; 06/1996
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We describe therapeutic challenges in a patient with breast cancer during follow-up after quadrantectomy. The patient had used hormone therapy for 5 years and then tamoxifen citrate, a selective estrogen receptor modulator, for 3 years. When seen by us, she was taking Arimidex, an aromatase inhibitor. In accord with recommendations in the literature, bisphosphonate therapy was prescribed by clinicians at the Menopause Center in cooperation with the Oncology Center. We suggest that cooperation between menopause centers and oncology centers should continue in the follow-up of such patients.
    Ochsner Journal 01/2009; 9(2):68-74.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Estrogen receptor status in breast cancer is associated with response to hormonal therapy and clinical outcome. The additional value of progesterone receptor (PR) has remained controversial. We examine the value of PR for prognosis and response to tamoxifen on a population-based series of 4,046 invasive early stage breast cancer patients. Clinical information for age at diagnosis, stage, pathology, treatment and outcome was assembled for the study cohort; the median follow-up was 12.4 years. PR status was determined by immunohistochemistry using a rabbit monoclonal antibody on tissue microarrays built from breast tumor surgical excisions. Survival analyses, Kaplan-Meier functions and Cox proportional hazards regression models were applied to assess the associations between PR and breast cancer specific survival. Progesterone receptor was positive in 51% of all cases and 67% of estrogen receptor positive (ER+) cases. Survival analyses for both the whole cohort and ER+ cases given tamoxifen therapy showed that patients with PR+ tumors had 24% higher relative probability for breast cancer specific survival as compared to PR- patients, adjusted for ER, HER2, age at diagnosis, grade, tumor size, lymph node status and lymphovascular invasion covariates. Higher PR expression showed stronger association with patient survival. Log-likelihood ratio tests of multivariate Cox proportional hazards regression models demonstrated that PR was an independent statistically significant factor for breast cancer specific survival in both the whole cohort and among ER+ cases treated with tamoxifen. PR adds significant prognostic value in breast cancer beyond that obtained with estrogen receptor alone.
    Breast Cancer Research and Treatment 03/2009; 119(1):53-61. DOI:10.1007/s10549-009-0318-0 · 4.20 Impact Factor